124,620 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by Federated Hermes Inc.

Federated Hermes Inc. acquired a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 124,620 shares of the company's stock, valued at approximately $1,973,000. Federated Hermes Inc. owned about 0.31% of Keros Therapeutics as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Handelsbanken Fonder AB increased its stake in shares of Keros Therapeutics by 11.3% in the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after buying an additional 1,100 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Keros Therapeutics by 19.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock worth $136,000 after acquiring an additional 1,372 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Keros Therapeutics by 2.6% in the 4th quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company's stock worth $1,549,000 after purchasing an additional 2,462 shares during the last quarter. Swiss National Bank raised its stake in shares of Keros Therapeutics by 4.8% in the 4th quarter. Swiss National Bank now owns 59,000 shares of the company's stock valued at $934,000 after purchasing an additional 2,700 shares in the last quarter. Finally, AlphaQuest LLC increased its holdings in Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after buying an additional 2,964 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the firm's stock in a transaction on Wednesday, April 9th. The shares were purchased at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now directly owns 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 22.90% of the company's stock.

Keros Therapeutics Price Performance

NASDAQ:KROS traded up $0.54 during trading hours on Friday, reaching $14.07. The company's stock had a trading volume of 1,347,070 shares, compared to its average volume of 781,948. Keros Therapeutics, Inc. has a one year low of $9.12 and a one year high of $72.37. The business's 50-day moving average is $11.09 and its 200-day moving average is $29.78. The company has a market cap of $570.71 million, a price-to-earnings ratio of -2.70 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.22. The business had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. On average, sell-side analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on KROS shares. Wedbush reiterated a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Piper Sandler decreased their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday, January 17th. Wells Fargo & Company dropped their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, February 27th. Cantor Fitzgerald lowered Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. Finally, Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $40.33.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.